These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate. Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783 [TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Shepherd J; Cooper K; Harris P; Picot J; Rose M Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404 [TBL] [Abstract][Full Text] [Related]
7. Recent therapeutic advances in juvenile idiopathic arthritis. Giancane G; Alongi A; Rosina S; Tibaldi J; Consolaro A; Ravelli A Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):476-487. PubMed ID: 29773268 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. Luca NJ; Burnett HF; Ungar WJ; Moretti ME; Beukelman T; Feldman BM; Schwartz G; Bayoumi AM Arthritis Care Res (Hoboken); 2016 Dec; 68(12):1803-1811. PubMed ID: 27059807 [TBL] [Abstract][Full Text] [Related]
9. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000 [TBL] [Abstract][Full Text] [Related]
10. Biologics in juvenile idiopathic arthritis: a narrative review. Vanoni F; Minoia F; Malattia C Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955 [TBL] [Abstract][Full Text] [Related]
11. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis. Sura A; Failing C; Sturza J; Stannard J; Riebschleger M Pediatr Rheumatol Online J; 2018 Jan; 16(1):2. PubMed ID: 29304824 [TBL] [Abstract][Full Text] [Related]
12. Predictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis. Batu ED; Sönmez HE; Gülhan B; Arıcı ZS; Topaloğlu R; Bilginer Y Turk J Pediatr; 2017; 59(1):6-12. PubMed ID: 29168357 [TBL] [Abstract][Full Text] [Related]
13. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Beukelman T; Xie F; Chen L; Baddley JW; Delzell E; Grijalva CG; Lewis JD; Ouellet-Hellstrom R; Patkar NM; Saag KG; Winthrop KL; Curtis JR; Arthritis Rheum; 2012 Aug; 64(8):2773-80. PubMed ID: 22569881 [TBL] [Abstract][Full Text] [Related]
14. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528 [TBL] [Abstract][Full Text] [Related]
15. Recommendations for the use of methotrexate in juvenile idiopathic arthritis. Niehues T; Lankisch P Paediatr Drugs; 2006; 8(6):347-56. PubMed ID: 17154642 [TBL] [Abstract][Full Text] [Related]
16. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study. Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate. Chickermane PR; Khubchandani RP Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527 [TBL] [Abstract][Full Text] [Related]
19. Comparing Canadian paediatric rheumatology practice to the 2019 ACR Juvenile Idiopathic Arthritis guidelines: results from the CAPRI Registry. Park J; Batthish M; Berard RA; Chédeville G; Proulx-Gauthier JP; Rumsey DG; Tucker LB; Wong S; Guzman J; Rheumatology (Oxford); 2023 Apr; 62(4):1616-1620. PubMed ID: 35977388 [TBL] [Abstract][Full Text] [Related]